Grant: Engage Grants Program
University of Ottawa
$21,500.00
Development of an Assay for Residual Protease Detection and Quantification
FY 2010-11
Summary
Biologics, pharmaceuticals produced through biological processes, are the most rapid growing sector of
pharmaceutical industry. Because of the complex nature of materials produced by biological processes,
characterization of process intermediates and final drug substances during manufacturing is extremely
challenging. The analytical methods required for this type of characterization are unique for each product and
process step. Development of robust analytical methods for characterizing these materials is crucial for the
ultimate safety of the patient and requires substantial research effort in analytical chemistry and biochemistry.
This proposal describes the basic research efforts to characterize the commercial protease used in the
preparation of the experimental therapeutic JX-594 and to design and develop a LC-MS/MS based quantitative
method for assay of residual protease in the JX-594. JX-594 is a promising cancer therapy developed by
Jennerex and it is currently in phase II clinical trials. In order to support phase III trials a residual protease
assay is required. The study outlined in this proposal will address a major concern of Jennerex
Biotherapeutics, strengthen the relationship between the University of Ottawa and the biotechnology sector,
support the development of a growing expertise of biologics development and manufacturing in Canada, and
enable the timely delivery of a promising new treatment to cancer patients in Canada.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
401889-2010
Name nom
Boddy, Christopher
Department département
Chemistry
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
21500
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Development of an Assay for Residual Protease Detection and Quantification
Keyword
NSERC
Application summary
Biologics, pharmaceuticals produced through biological processes, are the most rapid growing sector of
pharmaceutical industry. Because of the complex nature of materials produced by biological processes,
characterization of process intermediates and final drug substances during manufacturing is extremely
challenging. The analytical methods required for this type of characterization are unique for each product and
process step. Development of robust analytical methods for characterizing these materials is crucial for the
ultimate safety of the patient and requires substantial research effort in analytical chemistry and biochemistry.
This proposal describes the basic research efforts to characterize the commercial protease used in the
preparation of the experimental therapeutic JX-594 and to design and develop a LC-MS/MS based quantitative
method for assay of residual protease in the JX-594. JX-594 is a promising cancer therapy developed by
Jennerex and it is currently in phase II clinical trials. In order to support phase III trials a residual protease
assay is required. The study outlined in this proposal will address a major concern of Jennerex
Biotherapeutics, strengthen the relationship between the University of Ottawa and the biotechnology sector,
support the development of a growing expertise of biologics development and manufacturing in Canada, and
enable the timely delivery of a promising new treatment to cancer patients in Canada.